Home>Topics>Authors>Karen Andersen

Karen Andersen

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Apple’s Beats Buy: Desperation or Opportunity?

    Headlines

    Fri, 6 Jun 2014

    neutral effect on our fair value estimate, as we've stood by our belief that the drug is safe for approved uses. Karen Andersen BB&T's Credit Quality Remains Strong (Maintaining) BB&T BBT reported an excellent first quarter. The company

  2. This Undervalued Stock Is a Global Leader

    Video Reports

    Wed, 7 May 2014

    Karen Andersen : Baxter is a diversified health-care operation. They really operate in several different types of businesses. First, there

    Karen Andersen found at 0:00

    Karen Andersen : Baxter is a diversified health-care operation. They really operate in several different types of businesses. First, there is the bioscience business, which
  3. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Headlines

    Fri, 25 Apr 2014

    Fair Value Ratio*: 0.64 Morningstar analyst Karen Andersen thinks Vertex's VRTX expertise in chronic viral ..... significantly impact our Vectibix sales forecast. Karen Andersen Motorola Misses Forecasts Again (Maintaining) Motorola

  4. The Friday Five

    Video Reports

    Fri, 28 Mar 2014

    teams focus on doing a better job in those two different verticals. Even though there might be some extra costs, Karen Andersen , whose is our Baxter analyst, thinks that overall this would probably be a pretty good deal. She's not planning

    Karen Andersen found at 5:50

    those two different verticals. Even though there might be some extra costs, Karen Andersen , whose is our Baxter analyst, thinks that overall this would probably be a pretty good deal. She's not planning on making any
  5. 10 High-Conviction Purchases by Our Ultimate Stock-Pickers

    Headlines

    Tue, 19 Nov 2013

    focused on the development of small molecule drugs for the treatment of infectious diseases. Morningstar analyst Karen Andersen expanded further on this commentary, noting that while she thinks that Gilead paid a steep premium to bring Pharmasset's

  6. Announcing Morningstar's CEO of the Year Finalists

    Headlines

    Wed, 6 Nov 2013

    company into leading positions in the antifungal, HIV, and hepatitis C markets. Morningstar health-care analyst Karen Andersen expects Gilead's returns on invested capital to return to the mid-20% range by 2017 and believes that Gilead's

  7. Gilead Sciences Carving Out a Wider Moat

    Headlines

    Thu, 8 Aug 2013

    recently sat down with senior biotechnology analyst Karen Andersen to discuss Gilead Sciences GILD. A few weeks ago ..... terms of growth potential and patent protection? Karen Andersen , senior biotechnology analyst: Gilead started out

  8. Insights From the 'Best on the Street'

    Video Reports

    Thu, 9 May 2013

    right now, and also to talk about some of their favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow-moat

    Karen Andersen found at 3:14

    favorite picks for their radar screens in case there is a pullback. Karen Andersen : One of my favorite ideas right now is actually Gilead. It's a large-cap biotech name. We assign it a narrow-moat rating, and
  9. J&J to Swallow Vaccine Maker Crucell

    Commentary

    Fri, 17 Sep 2010

    short term. More important, over the long term, we believe Crucell's vaccine platform and novel biologics manufacturing platform open the door to major new markets for Johnson & Johnson. Karen Andersen , CFA, contributed to this note.

« Prev123Next »
Content Partners